On January 24, Fosun Pharma (600196/02196) issued an announcement that the drug registration application for salbutamol hydrochloride nebulized inhalation solution of its holding subsidiary Fosun Pharma (Xuzhou) Co., Ltd. was recently accepted by the State Drug Administration. The drug is a chemical drug independently developed by the company, mainly used to treat or prevent bronchospasm caused by reversible airway obstructive diseases in adults and children over 6 years old.

As of December 2024, the group's cumulative R&D investment in the drug is approximately 4.54 million yuan. According to data provided by IQVIA, the sales of salbutamol hydrochloride nebulized inhalation solution in China in 2023 will be approximately 1.009 billion yuan. The announcement pointed out that the drug still needs to pass GMP compliance inspection and obtain drug registration approval before commercial production, so the acceptance of the drug registration application will not have a significant impact on the group's current performance.

In the first three quarters of 2024, Fosun Pharma achieved revenue of 30.912 billion yuan and net profit attributable to shareholders of the parent company of 2.011 billion yuan.

https://finance.eastmoney.com/